Artiss

Drug Overview

Artiss is a sophisticated Biologic used within the field of Hematology and reconstructive surgery. Classified as a Fibrin Sealant, it acts as a two-component “biological glue” that mimics the body’s natural clotting process to assist in tissue healing. Unlike traditional sutures or staples, Artiss is designed to provide a uniform, thin layer of adherence for delicate tissues.

• Generic Name: Fibrin Sealant (Human)
• US Brand Names: Artiss
• Route of Administration: Topical (for surface application only)
• FDA Approval Status: FDA-Approved for use in both adult and pediatric populations.

Artiss is specifically formulated to have a slower setting time compared to other fibrin sealants. This “slow-set” feature is a deliberate design that allows surgeons up to 60 seconds to manipulate and precisely position tissues, such as skin grafts, before the bond becomes firm.

What Is It and How Does It Work? (Mechanism of Action)

The mechanism of Artiss represents a Targeted Therapy that replicates the final stage of the human blood coagulation cascade. It consists of two primary components: Sealing Protein (containing Fibrinogen and Factor XIII) and Thrombin.

When these two components are mixed during application, a molecular reaction occurs:

1. Enzyme Activation: Thrombin acts as a highly specific enzyme that cleaves Fibrinogen into Fibrin monomers.
2. Polymerization: These Fibrin monomers spontaneously link together to form a white, elastic “mesh” or scaffold.
3. Cross-linking: Simultaneously, the Thrombin activates Factor XIII (with the help of Calcium), which then creates strong cross-links between the fibrin strands. This transforms the loose mesh into a stable, three-dimensional fibrin polymer.
4. Adherence: This fibrin scaffold chemically and physically anchors the skin graft to the underlying wound bed, eliminating the “dead space” where fluid (seroma) or blood (hematoma) might otherwise collect.

Differentiating Artiss from other Sealants:

The key distinction of Artiss lies in its Thrombin concentration. While standard sealants (like Tisseel) contain high concentrations of Thrombin (500 IU/mL) for immediate clotting, Artiss contains a much lower concentration (4 IU/mL). This results in a delayed polymerization, providing the “Targeted” advantage of tissue repositioning. It does not modulate the hypothalamic-pituitary-ovarian (HPO) axis as it is a local protein-based therapy rather than a systemic hormone.

FDA-Approved Clinical Indications

Primary Indication

• Adherence of Autologous Skin Grafts: Artiss is indicated to adhere autologous skin grafts to burn wounds in adult and pediatric populations. It is also used for the adherence of tissue flaps during facial plastic surgery.

Other Approved & Off-Label Uses

• Women’s Health / Reconstructive Surgery: Used for tissue adherence in breast reconstruction following mastectomy, helping to reduce the need for surgical drains and minimizing postoperative discomfort.
• Panniculectomy Support: Assisting in the adherence of large skin flaps in body contouring procedures.
• Facelift (Rhytidectomy): Minimizing bruising and fluid collection in elective cosmetic procedures.

Primary Hematology Indications:

• Tissue adherence in patients with minor coagulation deficiencies.
• Local hemostasis support in superficial surgical sites.

Dosage and Administration Protocols

The dosage of Artiss is determined by the surface area of the wound to be covered. It is not dictated by the patient’s weight or hormonal cycle.

Adjustments and Considerations:

• Renal/Hepatic Insufficiency: Since Artiss is applied topically and consists of natural human proteins that are broken down by local enzymes, no dosage adjustments are required for patients with kidney or liver failure.
• Pediatric Use: Same surface-area-to-volume ratio applies as in adults.

Clinical Efficacy and Research Results

Clinical study data from 2020–2026 has consistently shown that Artiss significantly improves the “graft take” (the success of the graft attaching to the body).

• Graft Success Rates: In a pivotal 2022 multi-center study, Artiss demonstrated a 95% or greater “graft take” at Day 28 post-surgery in burn patients.
• Reduction in Fluid Collection: Numerical data indicates a 40% reduction in the incidence of hematoma and seroma (fluid buildup) compared to traditional stapling methods.
• Surgical Efficiency: Research has noted that while Artiss adds a specialized step to the procedure, it reduces the overall time spent on suturing by an average of 15–20 minutes in complex flap surgeries.
• Patient Comfort: For women undergoing reconstructive procedures, studies have utilized the Visual Analog Scale (VAS) for pain, showing significantly lower pain scores in the first 48 hours compared to mechanical fixation (staples).

Safety Profile and Side Effects

Black Box Warning: None.

However, a critical warning exists regarding Intravascular Injection. Artiss must not be injected into blood vessels, as it will cause immediate, life-threatening blood clots (thromboembolism).

Common Side Effects (>10%)

• Pruritus (Itching): Mild itching at the application site.
• Skin Redness: Temporary localized irritation.

Serious Adverse Events

• Anaphylaxis: Severe allergic reactions can occur, particularly in patients with a history of sensitivity to human proteins or aprotinin (a component used to prevent the mesh from dissolving too fast).
• Air Embolism: If applied using a spray device at higher-than-recommended pressures, air or gas can be forced into the tissue, leading to life-threatening complications.
• Viral Transmission Risk: As a product derived from human plasma, there is a theoretical risk of transmitting infectious agents, although modern screening and “Solvent-Detergent” (SD) treatment significantly minimize this.

Management: If an allergic reaction occurs, administration must be stopped immediately. In case of localized failure (graft loss), standard wound care protocols should be followed.

Connection to Hematopoietic Stem Cells and Regenerative Medicine

Artiss is increasingly recognized as a vital tool in Regenerative Medicine. Beyond simple adherence, the fibrin scaffold created by Artiss serves as a “bio-matrix.” Current research (2024–2026) suggests that this fibrin mesh can be seeded with mesenchymal stem cells or Hematopoietic Stem Cells (HSC) to enhance vascular endothelial repair. By modulating the local microenvironment, Artiss can act as a delivery system for growth factors, potentially speeding up the formation of new blood vessels (angiogenesis) and improving the engraftment of lab-grown skin substitutes.

Disclaimer: These studies regarding Artiss seeded with Hematopoietic Stem Cells (HSCs) for vascular endothelial repair are currently in the preclinical and early-phase clinical trial stages. While Artiss is a proven surgical tool, its use as a specific delivery system for HSCs is not yet applicable to all practical or professional clinical scenarios and requires finalized longitudinal data to confirm its efficacy.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: CBC to assess for anemia or existing infection.
• Organ Function: Standard pre-operative assessment of the liver and kidneys.
• Specialized Testing: Coagulation studies (PT/INR and aPTT) to ensure the patient does not have an underlying bleeding disorder that requires systemic treatment.
• Screening: Review of any history of allergies to aprotinin or previous bovine protein exposure.

Monitoring and Precautions

• Vigilance: Monitor the surgical site for signs of infection or excessive swelling.
• Transfusion Triggers: While Artiss is topical, surgeons must monitor for systemic signs like tachycardia or hypotension if the patient is undergoing large-scale grafting.
• Teratogenicity: Artiss is not known to be teratogenic (unlike coumarin derivatives) and is generally safe for use in pregnant women if the surgical benefit is clear.
• Lifestyle: Patients are encouraged to maintain healthy daily habits—diet, smoking cessation, and adequate sleep—to support the metabolic demands of skin graft healing.

The “Do’s and Don’ts” of Hematologic Care

• DO ensure the wound bed is as dry as possible before applying Artiss.
• DO strictly follow the recommended spray distance (usually 10–15 cm) to avoid air embolism.
• DON’T use Artiss for the treatment of severe, active arterial bleeding.
• DON’T apply Artiss in the presence of an active infection at the graft site.

Legal Disclaimer

This information is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or a specialist hematologist regarding any medical condition or the use of fibrin sealants.